Caleres Regular Quarterly Dividend

ST. LOUIS--(BUSINESS WIRE)-- The quarterly dividend for Caleres (NYSE: CAL) (caleres.com) of $0.07 per share will be payable on April 9, 2019, to shareholders of record as of March 26, 2019.

This dividend will be the 384th consecutive quarterly dividend paid by the company.

About Caleres
Caleres is a diverse portfolio of global footwear brands. Our products are available virtually everywhere - in the over 1,200 retail stores we operate, in hundreds of major department and specialty stores, on our branded e-commerce sites, and on many additional third-party retail websites. Famous Footwear offers great casual and athletic brands for the entire family with convenient, curated, affordable collections. Sam Edelman keeps expressive women in step with the latest trends in a playful, whimsical way. Naturalizer shoes are beautiful from the inside out, with elegant simplicity and legendary fit re-imagined for today’s consumer. Allen Edmonds combines old world craft with new world technology to create luxe footwear for the discerning man who wants sophisticated, modern classics. Rounding out our family of brands are Vionic, Vince, Franco Sarto, Dr. Scholl’s Shoes, LifeStride, Via Spiga, Diane von Furstenberg, Blowfish Malibu, Bzees, Carlos by Carlos Santana, Circus by Sam Edelman, Fergie and Ryka. Combined, these brands make Caleres a company with both a legacy and a mission. Our legacy is our more than 140 years of craftsmanship and our passion for fit, while our mission is to continue to inspire people to feel good… feet first. Visit caleres.com to learn more about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190314005818/en/

Peggy Reilly Tharp, Caleres
(314) 854-4134, [email protected]

Source: Caleres

You May Also Be Interested In

• Digital Heroes Surpasses 2,000 Brand Clients and Publishes 1,073 Shopify Buyer Guides as Agency Expands Global Shopify Development Operations
• How To Trade Memecoins In 2026: MemeToro Offers A Structured Example With AI Agent
• Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain